AC
Background
I'm a biotech CFO with fifteen years inside UK drug-development companies, from seed through Series C. I'm currently CFO at Helix Therapeutics, where I joined pre-Series A and built the finance function through to a £58m Series C; prior to that I led the Series A raise at Stellaris Bio and held CFO seats at Arclight Ph…
Experience6 yrsCompanies8
Career History
Dec 2025 – Present7 moCFO at Helix TherapeuticsLondon, England, United Kingdom
Pre-Series A → Series C9 → 64 FTEs£12M Series A · £28M Series B · £58M Series COncology · Solid tumour
Joined at 9 FTEs pre-Series A, closed £12M A and £28M B in-seat, then led the £58M Series C that took Helix to 64 staff and IND-ready.
Nov 2025 – Present8 moCFO at Stellaris Bio
Seed → Series A7 → 22 FTEs£19M Series APlatform therapeutics
Built the finance function from scratch at 7 FTEs and led the £19M Series A close with Sofinnova and a UK syndicate from inside the company.
Jun 2025 – Present1 yr 1 moPortfolio CFO at Northlight Genomics
Portfolio CFO · 3 cos11–50 FTEsSeed / Series A
Parachuted across three seed-to-Series-A oncology and genomics portfolio companies, standing up reporting, R&D tax credit claims and EIS rounds.
Mar 2025 – Present1 yr 4 moDirector at Verdant Biosciences
Education
PhD — Northbridge University (2013–2020)